KAMR Amarillo on MSN17h
ASCO GU Symposium announces new findings on tumor reduction and survival outcomes in advanced renal cell carcinomaThomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at ...
The following is a summary of “Risk factors for renal insufficiency and survival implications after radical nephrectomy and ...
Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...
Padcev plus Keytruda was found to maintain benefit over chemotherapy in untreated locally advanced or metastatic urothelial ...
There are currently 82,000 incident cases of RCC annually in the United States (account for 3–5% of cancers), with 15,000 deaths annually in the United States. The overall 5-year mortality risk is ~30 ...
In the initial publication in 2021, the KETYNOTE-564 trial demonstrated that adjuvant pembrolizumab was associated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback